Oyster Point Pharma Inc.’s treatment for dry eye disease became the first U.S. approved nasal spray for the chronic condition on Oct. 18, sending the drug developer’s shares higher.
Russia will test a nasal spray form of the Sputnik V vaccine against Covid-19 among adult volunteers, according to a state document published on Oct. 12, as the country struggles to rein in rising numbers of infections and deaths.
Codagenix Inc. announced favorable safety and immunogenicity data from a Phase I dose-escalation trial of the company’s single-dose intranasal COVI-VAC vaccine, and London-based pHOXBIO Ltd. reported results from a pivotal phase II/III study of the novel prophylactic nasal spray pHOXWELL.
Indian vaccine maker Bharat Biotech’s nasal Covid-19 vaccine candidate received regulatory approval for mid-stage to late-stage trials, the government’s ministry of science and technology said in a statement on Aug. 13.
Oyster Point’s New Drug Application (NDA) for the dry eye disease therapy OC-01 was accepted for FDA regulatory review on the back of positive Phase III data.
Auris Medical shares skyrocketed after the announcement of lab test results that appeared to show the company’s nasal spray AM-301 could potentially protect users against Covid-19, according to Business Insider.
Ena Respiratory said a nasal spray that the Australian biotech company is developing to improve the human immune system to fight common cold and flu significantly reduced the growth of the coronavirus in a recent study on animals.
Neurelis Inc. announced the commercial availability of Valtoco (diazepam nasal spray) for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient’s usual seizure pattern in adult and pediatric patients 6 years of age and older.
The collaboration will utilize EVERSANA’s integrated suite of outsourced services to commercialize and distribute Evoke Pharma Inc.’s Gimoti in the United States.
UCB announced that the U.S. Food and Drug Administration approved a New Drug Application for the company’s anti-epileptic drug Nayzilam (midazolam) nasal spray CIV.